BR112012002578A2 - composição para o tratamento da fibrose cística - Google Patents

composição para o tratamento da fibrose cística

Info

Publication number
BR112012002578A2
BR112012002578A2 BR112012002578A BR112012002578A BR112012002578A2 BR 112012002578 A2 BR112012002578 A2 BR 112012002578A2 BR 112012002578 A BR112012002578 A BR 112012002578A BR 112012002578 A BR112012002578 A BR 112012002578A BR 112012002578 A2 BR112012002578 A2 BR 112012002578A2
Authority
BR
Brazil
Prior art keywords
treatment
composition
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
BR112012002578A
Other languages
English (en)
Other versions
BR112012002578B8 (pt
BR112012002578B1 (pt
Inventor
Christina Gloeckel
Michael Freissmuth
Xaver Koenig
Original Assignee
Scipharm Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sàrl filed Critical Scipharm Sàrl
Publication of BR112012002578A2 publication Critical patent/BR112012002578A2/pt
Publication of BR112012002578B1 publication Critical patent/BR112012002578B1/pt
Publication of BR112012002578B8 publication Critical patent/BR112012002578B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012002578A 2009-08-07 2010-08-05 usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística BR112012002578B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167491.1 2009-08-07
EP09167491 2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis

Publications (3)

Publication Number Publication Date
BR112012002578A2 true BR112012002578A2 (pt) 2016-03-15
BR112012002578B1 BR112012002578B1 (pt) 2021-01-12
BR112012002578B8 BR112012002578B8 (pt) 2021-05-25

Family

ID=41382119

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002578A BR112012002578B8 (pt) 2009-08-07 2010-08-05 usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística

Country Status (26)

Country Link
US (2) US20120184622A1 (pt)
EP (1) EP2461812B1 (pt)
JP (1) JP5877787B2 (pt)
KR (1) KR101729800B1 (pt)
CN (1) CN102548559B (pt)
AU (1) AU2010280684B2 (pt)
BR (1) BR112012002578B8 (pt)
CA (1) CA2770066C (pt)
CL (1) CL2012000319A1 (pt)
CY (1) CY1114983T1 (pt)
DK (1) DK2461812T3 (pt)
EA (1) EA023720B1 (pt)
ES (1) ES2451790T3 (pt)
GT (1) GT201200038A (pt)
HK (1) HK1165293A1 (pt)
HN (1) HN2012000297A (pt)
HR (1) HRP20140277T1 (pt)
IL (1) IL217899B (pt)
PL (1) PL2461812T3 (pt)
PT (1) PT2461812E (pt)
RS (1) RS53234B (pt)
SG (1) SG178315A1 (pt)
SI (1) SI2461812T1 (pt)
SM (1) SMT201400057B (pt)
WO (1) WO2011015630A1 (pt)
ZA (1) ZA201200790B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
PL2663313T3 (pl) 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
EA029760B1 (ru) 2011-02-07 2018-05-31 Сифарм Сарл ПРИМЕНЕНИЕ КОМПОЗИЦИИ ПРОСТАЦИКЛИНА И ИНГИБИТОРА ФОСФОДИЭСТЕРАЗЫ 4 ИЛИ ИХ АНАЛОГОВ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА И УВЕЛИЧЕНИЯ цАМФ В ЭПИТЕЛИАЛЬНЫХ КЛЕТКАХ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN108947843A (zh) 2013-10-25 2018-12-07 英斯梅德股份有限公司 前列环素化合物、其组合物及使用方法
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
WO2020223237A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6310898A (en) * 1997-03-14 1998-10-12 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
AU4976599A (en) * 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN102697790A (zh) * 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US7893050B2 (en) * 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2641393C (en) * 2006-02-03 2014-12-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
WO2008098196A1 (en) * 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma

Also Published As

Publication number Publication date
PT2461812E (pt) 2014-04-07
EP2461812A1 (en) 2012-06-13
HK1165293A1 (en) 2012-10-05
SG178315A1 (en) 2012-03-29
IL217899B (en) 2018-05-31
EP2461812B1 (en) 2014-01-01
CA2770066A1 (en) 2011-02-10
AU2010280684B2 (en) 2016-07-28
US20120184622A1 (en) 2012-07-19
HN2012000297A (es) 2015-05-18
KR20120056819A (ko) 2012-06-04
JP5877787B2 (ja) 2016-03-08
EA201200253A1 (ru) 2012-07-30
ZA201200790B (en) 2013-05-29
JP2013501032A (ja) 2013-01-10
CN102548559B (zh) 2013-12-25
SI2461812T1 (sl) 2014-05-30
CN102548559A (zh) 2012-07-04
WO2011015630A1 (en) 2011-02-10
EA023720B1 (ru) 2016-07-29
ES2451790T3 (es) 2014-03-28
HRP20140277T1 (hr) 2014-04-25
KR101729800B1 (ko) 2017-04-24
PL2461812T3 (pl) 2014-12-31
CL2012000319A1 (es) 2012-09-14
RS53234B (en) 2014-08-29
CA2770066C (en) 2018-10-23
US10086001B2 (en) 2018-10-02
DK2461812T3 (da) 2014-04-07
US20160175319A1 (en) 2016-06-23
AU2010280684A1 (en) 2012-02-23
IL217899A0 (en) 2012-03-29
BR112012002578B8 (pt) 2021-05-25
GT201200038A (es) 2015-01-16
CY1114983T1 (el) 2016-12-14
SMT201400057B (it) 2014-07-07
BR112012002578B1 (pt) 2021-01-12

Similar Documents

Publication Publication Date Title
BR112012002578A2 (pt) composição para o tratamento da fibrose cística
SMT201700099B (it) Nuova composizione per il trattamento di fibrosi cistica
IL216800A (en) Preparation for the treatment of dry eye syndrome
HK1172269A1 (en) Pharmaceutical composition for treatment of dry eye syndrome
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
IL264118A (en) Pharmaceutical preparation of amorphous acyl sulfonamide
BRPI0822264A2 (pt) Dapsona para tratar rosácea
BRPI0915905A2 (pt) uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
BRPI0914947A2 (pt) composições para o tratamento de queda de cabelo
BRPI0810762A2 (pt) Composição para tratamento da água
DK2628798T3 (da) Profylaktisk eller terapeutisk middel mod fibrose
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
IT1394514B1 (it) Nuova composizione per il trattamento di pigmentazione ecchimotiche
BRPI0922216A2 (pt) tratamento para glomerulonefrite
BRPI1009131A2 (pt) composição farmacêutica compreendendo aliscireno
GB201000499D0 (en) Treatment of cystic fibrosis
ES1073286Y (es) Aplicador para eliminar el vello
DOP2009000156A (es) Nueva utilizacion terapeutica para el tratamiento de las leucemias
UY3885Q (es) Plancha para el cabello

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SCIPHARM SA RL (LU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2734 DE 30-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.